Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRockwood Strat. Regulatory News (RKW)

Share Price Information for Rockwood Strat. (RKW)

Share Price is delayed by 15 minutes
Get Live Data
312.00    -5.00 (-1.58%)
Bid:
310.00
Ask:
312.00
Spread: 2.00 (0.645%)
Market Cap: £180.07m
RKW Live PriceLast checked at - London Stock Exchange

Intraday Rockwood Strat. Share Chart

Results analysis from Kepler Trust Intelligence

Today 09:46

RNS Number : 8522I
Rockwood Strategic PLC
18 June 2026
 

Rockwood Strategic (RKW)

18/06/2026

Results analysis from Kepler Trust Intelligence

Rockwood Strategic (RKW) released annual results for the year to 31/03/2026, reporting NAV and share price total returns of 7.1% and 2.4%, respectively. Whilst the trust has no formal benchmark, comparator indices, the FTSE Small Cap (ex-ITs) and the FTSE AIM All-Share Index, returned 8.9% and 5.1% over the same period.

Capital Limited was a strong driver over this period, up almost 100% on a recovering Laboratories division and growing exposure to mining capex. Vanquis Banking wasn't far behind, rising 93%, benefitting from falling costs which helped return it to profitability.There were some challenges. The portfolio took a write down on Argentex, the FX firm that collapsed after high-risk client trades were caught out by sharp dollar moves. Further, in March 2026, the market reaction to US military action against Iran pushed up energy prices and inflation expectations, denting hopes for further rate cuts, both weighing on equity markets and RKW's NAV, in the last month of its reporting period.

During the reported period, RKW's shares maintained an average 1.2% premium to NAV. However, President Trump's actions in the Persian Gulf unnerved investors pushing the trust to a small 2.7% discount at the reporting period-end, albeit briefly, as RKW moved back to a premium rating shortly after. At the time of writing, it trades at a premium of 2.7%.

Kepler View

Rockwood Strategic (RKW) has delivered exceptional long-term returns for investors, with a NAV total return of almost 100% over the past five-years. We think this record is a clear demonstration of Richard Staveley's approach in action, hunting from the bottom-up for idiosyncratic, overlooked and undervalued companies with genuine potential to grow their intrinsic value meaningfully. The key lies not only in identifying catalysts capable of unlocking that value, but for many of the trust's largest holdings, the influence Richard and team can assert to affect change, shaping board and management decisions directly. A great example of the positive impact this influence can have is via the investment in Galliford Try. Over time the position re-rated strongly, supported by Richard and the team's regularly engagement around capital allocation, prompting them to sell the position in its 2026 financial year, realising a 48% IRR and 2.4× money-multiple.

However, set against this record, the latest full year results running through to March 2026 may look somewhat out of step, with RKW delivering a NAV total return of 7.1%. On closer inspection, however, we would argue that this is not an entirely accurate reflection of the portfolio's progress over the year. Over its financial year, to February-end, the trust had delivered a NAV total return of 19.4%, but following the conflict in the Middle East, both wider equity markets and the portfolio's valuation were hit hard. The weakness in March, the last month of its annual reporting period, was a big driver in RKW's drop to a high single digit return. Since the period end to 16/06/2026, performance has rebounded sharply, with a NAV total return of 18.8%.

Looking ahead, we believe the broader backdrop for UK small and micro caps remains constructive and developments in artificial intelligence, could also be a net positive for many of the portfolio's holdings, including its current largest position, RM. Richard is alert to the risks too, including the weaponisation of AI for cybercrime, but expects most portfolio companies to benefit over time, with several already seeing improved operational productivity. On a policy level, we think the reduction in the cash ISA allowance from April 2027 has some merit, nudging savers towards investing in the market, a tacit acknowledgement from the government that the UK market remains under-owned by its own population. That said, we share Richard and team's frustration at the scale of opportunity still being missed. With the UK market having now outperformed the S&P 500 for a second consecutive year, and UK equities remaining at comparatively attractive valuations, broader policy support continues to lag that opportunity. For investors willing to look past short-term noise, we think the Richard's approach holds potential to unlock meaningful, differentiated value in the UK market, and it is precisely this disconnect between fundamentals and flows where managers like Richard continue to demonstrate their stock-picking edge.

CLICK HERE TO READ THE FULL REPORT  Visit Kepler Trust Intelligence for more high quality independent investment trust research.

Important information

This report has been issued by Kepler Partners LLP. The analyst who has prepared this report is aware that Kepler Partners LLP has a relationship with the company covered in this report and/or a conflict of interest which may impair the objectivity of the research.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that if you are a private investor independent financial advice should be taken before making any investment or financial decision.

Kepler Partners is not authorised to make recommendations to retail clients. This report has been issued by Kepler Partners LLP, is based on factual information only, is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.

The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. In particular, this website is exclusively for non-US Persons. Persons who access this information are required to inform themselves and to comply with any such restrictions.

The information contained in this website is not intended to constitute, and should not be construed as, investment advice. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.

This is not an official confirmation of terms and is not a recommendation, offer or solicitation to buy or sell or take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.

Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm's internal rules. A copy of the firm's Conflict of Interest policy is available on request.

PLEASE SEE ALSO OUR TERMS AND CONDITIONS

Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority (FRN 480590), registered in England and Wales at 70 Conduit Street, London W1S 2GF with registered number OC334771.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAVVLBFQQLZBBZ
Date   Source Headline
18th Jun 20269:46 amRNS-RResults analysis from Kepler Trust Intelligence
18th Jun 20267:00 amRNSIssue of Equity and TVR
17th Jun 20267:00 amRNSFull year results to 31 March 2026
17th Jun 20267:00 amRNSIssue of Equity and TVR
15th Jun 20263:56 pmRNSNet Asset Value(s)
9th Jun 20267:00 amRNSIssue of Equity and TVR
8th Jun 20263:05 pmRNSNet Asset Value(s)
8th Jun 20267:00 amRNSIssue of Equity and TVR
5th Jun 20267:00 amRNSIssue of Equity and TVR
3rd Jun 20267:00 amRNSIssue of Equity and TVR
1st Jun 20264:54 pmRNSNet Asset Value(s)
1st Jun 20267:00 amRNSIssue of Equity and TVR
29th May 20267:00 amRNSIssue of Equity
26th May 20264:18 pmRNSNet Asset Value(s)
18th May 20265:22 pmRNSNet Asset Value(s)
15th May 20267:00 amRNSIssue of Equity and TVR
14th May 20267:00 amRNSIssue of Equity and TVR
11th May 20264:10 pmRNSNet Asset Value(s)
8th May 20267:00 amRNSInvestor Presentation
5th May 20262:32 pmRNSNet Asset Value(s)
1st May 20263:57 pmRNSNet Asset Value(s)
27th Apr 20264:01 pmRNSNet Asset Value(s)
22nd Apr 20267:00 amRNSIssue of Equity and TVR
20th Apr 20262:58 pmRNSNet Asset Value(s)
20th Apr 20267:00 amRNSIssue of Equity and TVR
13th Apr 20263:12 pmRNSNet Asset Value(s)
7th Apr 20264:16 pmRNSNet Asset Value(s)
7th Apr 20262:00 pmRNSDirector Declaration
1st Apr 20264:54 pmRNSNet Asset Value(s)
1st Apr 20267:00 amRNSDirector/PDMR Shareholding
30th Mar 20266:24 pmRNSNet Asset Value(s)
25th Mar 20267:00 amRNSIssue of Equity and TVR
19th Mar 20267:00 amRNSDirector/PDMR Shareholding
18th Mar 202610:30 amRNSDirector/PDMR Shareholding
16th Mar 20263:49 pmRNSNet Asset Value(s)
11th Mar 20267:00 amRNSIssue of Equity and TVR
9th Mar 20262:51 pmRNSNet Asset Value(s)
9th Mar 20267:00 amRNSIssue of Equity and TVR
4th Mar 20264:22 pmRNSHolding(s) in Company
3rd Mar 20267:00 amRNSIssue of Equity and TVR
2nd Mar 20264:44 pmRNSNet Asset Value(s)
2nd Mar 20267:00 amRNSIssue of Equity and TVR
27th Feb 20267:00 amRNSIssue of Equity and TVR
26th Feb 20267:00 amRNSIssue of Equity and TVR
25th Feb 20267:00 amRNSIssue of Equity and TVR
23rd Feb 20263:34 pmRNSNet Asset Value(s)
23rd Feb 20267:00 amRNSIssue of Equity and TVR
19th Feb 20267:00 amRNSIssue of Equity and TVR
18th Feb 20267:00 amRNSIssue of Equity and TVR
16th Feb 20264:02 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.